| Hyperthermia Combined with Radiation and Androgen Therapy Provides ...
BSD Medical Corp. (AMEX:BSM) today announced that the International Journal of Hyperthermia has published the preliminary results of a phase II clinical study involving 144 patients with locally advanced prostate cancer. In this study BSD Medical's BSD-2000 hyperthermia system was used to deliver local hyperthermia combined with conformal radiation therapy and androgen suppression therapy in the treatment of prostate cancer. Hyperthermia combined with radiation and androgen therapy demonstrated results in survival similar to treatments using higher radiation doses, with no significant side effects associated with either hyperthermia or radiation therapy. The report is entitled "Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: Preliminary results of a prospective phase II study" (see Int.
TGen finds key prostate cancer gene
Scientists from TGen and other research facilities and universities have identified a gene that may be linked to an aggressive form of prostate cancer, a finding that researchers say could advance the treatment of the disease. The research eventually could yield a simple blood test to help doctors and patients determine the best course of treatment for the disease, scientists say. That would be an important step because physicians now have no way of knowing whether a prostate tumor is dangerous, prompting many unnecessary radiation treatments and surgeries that can have harmful side effects. The scientists believe the gene, called DAB2IP, aids in suppressing tumor growth. When the gene takes on a variant form, the body's natural protection is stripped away, allowing prostate cancer to spread unchecked, researchers say.
IDM Pharma Announces Upcoming Clinical Data Presentations
IDM Pharma Announces Upcoming Clinical Data Presentations IRVINE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (NASDAQ: IDMI) , a biotechnology company focused on the development of innovative cancer therapies, today announced details on clinical data presentations evaluating three of the Company's pipeline compounds to be presented at upcoming medical congresses. "Osteosarcoma: Improved Outcome of Muramyl Tripeptide (MTP) to Cisplatin, Doxorubicin, High Dose Methotrexate +/- Ifosfamide." Dr. Paul Meyers, principal investigator, vice chairman, department of pediatrics at Memorial Sloan Kettering Cancer Center Abstract #780 The 39th Congress of International Society of Pediatric Oncology (SIOP) -- Mumbai, India Poster presentation -- Friday, November 2, 4:30 -- 6 a.m.
Raiding the Himalayas
He or she should have attained the age 16 and not more than 45. However, for skiing and basic adventure courses, the minimum age is 10. For advanced courses, the candidate should have completed the basic course with �A� grade. Specialisations The Manali institute and its centres give exposure in rock climbing, rappelling, river crossing, trekking, camping, map reading, skiing, swimming, water safety and rescue, canoeing, kayaking, rowing, sailing, water surfing, skiing, white-water rafting, etc. Training programmes The 26-day basic mountaineering course will start on October 1, while the 28-day �method of instruction mountaineering course� will start on September 29. The Manali institute will conduct both courses. The duration of various skiing courses is 14 days. These courses will be conducted between January and April.
EBSCO Publishing's Medical Review Board
On an annual basis, experts must provide EBSCO Publishing with an updated copy of their professional credentials or licensure. EBSCO Publishing agrees that it will not edit the experts' advice in a manner that causally changes its original meaning; will not require an expert to promote a product, device, or service; and will not ask experts to provide advice for information that is outside their area of professional expertise. Robert C. Algar, MD received his medical degree from Vanderbilt University School of Medicine. He performed his residency at Cornell Medical Center serving New York Hospital and Sloan Kettering Memorial Cancer Center. In addition, he completed fellowship training in Clinical Neurophysiology. Dr. Algar is currently practicing as a board certified Neurologist in the San Francisco Bay Area.
Hiroshima Bomber Unrepentant till Death
I'm making a partial exception to my self-imposed rule of not speaking ill of the dead. Paul Tibbets, the pilot who dropped the atom bomb on Hiroshima, died Nov. 1, unrepentant till the very end. "I wanted to do everything that I could to subdue Japan. I wanted to kill the bastards. That was the attitude of the United States in those years," he told an interviewer in 1995. "I have been convinced that we saved more lives than we took. It would have been morally wrong if we'd have had that weapon and not used it and let a million more people die." There was only one problem with his analysis: He was just plain wrong. In the last few decades, there has been a whole slew of studies showing that the dropping of the bomb was-militarily and strategically-completely unnecessary.
Introgen Therapeutics Highlights Summary ADVEXIN Data At The Third ...
Introgen Therapeutics, Inc. (NASDAQ:INGN) reported summary data from clinical studies of its lead product, ADVEXIN®. These data confirm and extend previous biomarker data correlating the abnormal p53 biomarker with increased tumor responses following ADVEXIN treatment and support its use as a biomarker to predict ADVEXIN efficacy. Additionally, data are being presented demonstrating clinical benefit of ADVEXIN in a patient with a rare inherited form of cancer known as Li-Fraumeni Syndrome (LFS), a genetic disorder characterized by inherited mutations in the p53 tumor suppressor gene. These data have been the subject of previous presentations at scientific and medical conferences.
These data are being presented at the 3rd International Workshop on Mutant p53 and the Symposium on Li-Fraumeni Syndrome in Lyon, France, organized by the International Agency for Research on Cancer and the European community.
|
